Article: Nicotinamide Riboside Prevents Diabetic Cardiomyopathy: Preclinical Findings

Sep 23, 2025 Cardiovascular Disease Cardiovascular Health Diabetes Preclinical

Nicotinamide Riboside Prevents Diabetic Cardiomyopathy: Preclinical Findings

Synopsis

In a mouse model of diabetic cardiomyopathy (DCM) induced by STZ and a high-fat diet, nicotinamide riboside (NR) (400 mg/kg/day) lowered fasting glucose and insulin levels, improved diastolic function, and reduced cardiomyocyte hypertrophy and fibrosis. NR increased cardiac 5-hydroxymethylcytosine (5hmC), activated AMPK, enhanced TET enzyme activity—especially stabilizing TET2—and improved TCA cycle metabolism and mitochondrial biogenesis. These findings show that NR protects the diabetic heart by promoting active DNA demethylation and restoring mitochondrial function, supporting NR as a potential therapeutic strategy for preventing and treating DCM.

Journal

Food Science and Human Wellness

See Published Study

Cardiovascular Health

NR Restores NAD+ and Protects Heart Cells from Fatty Acid Damage: Preclinical Findings

Synopsis This study looks at how fatty acids (FAs) affect heart cells (cardiomyocytes) by reducing their ability to take in glucose, especially after a lack of oxygen (ischemia–reperfusion injury)...